隐匿性乳腺癌的MRI表现与病理特征
该回顾性研究分析了34例隐匿性乳腺癌患者的MRI表现与临床病理特征,MRI检出原发灶17例,以小型肿块型或非肿块样强化为主。有完整免疫组化结果的23例中,ER阳性率47.8%、PR阳性率43.5%、HER-2阳性率30.4%,Ki-67高表达87.0%,分子亚型以Luminal B型最常见(43.5%)。
要点
- 隐匿性乳腺癌原发灶MRI常表现为小型肿块或局灶性、线样、段样分布的非肿块样强化
- ER、PR阳性率较低,HER-2阳性率较高,Ki-67指数较高
- 分子亚型以Luminal B型最多见,其次为三阴性乳腺癌
核心结论
- 隐匿性乳腺癌原发灶MRI常表现为体积较小的肿块型病变及局灶性、线样或段样分布的非肿块样强化。
- 隐匿性乳腺癌ER、PR阳性率低,HER-2阳性率高,Ki-67指数较高,分子亚型以Luminal B型最常见。
研究设计与样本
- 回顾性分析34例隐匿性乳腺癌患者的MRI影像报告(依据2013年BI-RADS)及临床病理资料。
主要发现
- 34例中24例行乳腺癌改良根治术,18例病理切片可见原发癌灶;MRI检出原发灶17例。
- MRI检出肿块型病变6例(直径0.6~1.2 cm,平均0.9 cm),非肿块样强化11例(线样4例、段样3例、局灶性3例、区域性1例)。
- TIC类型Ⅰ型5例、Ⅱ型10例、Ⅲ型2例。
- 有完整免疫组化结果23例:ER阳性11例(47.8%)、PR阳性10例(43.5%)、HER-2阳性7例(30.4%)、Ki-67高表达(>14%)20例(87.0%)。
- 分子亚型:Luminal A型1例(4.3%)、Luminal B型10例(43.5%)、三阴性乳腺癌7例(30.4%)、HER-2过表达5例(21.7%)。
临床怎么用
- 对腋窝淋巴结转移而乳腺未触及明确肿块的患者,可结合MRI形态学与TIC评估乳腺内隐匿原发灶。
- 病理免疫组化应关注ER、PR、HER-2及Ki-67,以指导分子分型与后续治疗决策。
局限性
- 本研究为单中心回顾性分析,样本量34例,部分患者免疫组化结果不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the magnetic resonance imaging (MRI) findings and clinicopathological features of primary lesions in patients with occult breast cancer (OBC). Methods: The imaging reports from the Breast Imaging Reporting and Data System in 2013 were retrospectively analyzed to investigate the morphology and the time signal intensity curve (TIC) of breast lesions in patients with OBC. The clinical and pathological characteristics of these patients were also included. Results: A total of 34 patients were enrolled. Among these patients, 24 patients underwent modified radical mastectomy and 18 of them had primary breast carcinoma in pathological sections. MRI detected 17 cases of primary lesions, including six masse lesions with a diameter of 0.6-1.2 cm (average 0.9 cm), and 11 non-mass lesions with four linear distributions, three segmental distributions, three focal distributions, and one regions distribution. Five patients had TIC typeⅠprimary lesions, ten had TIC type Ⅱ primary lesions, and two had TIC type Ⅲ primary lesions. Among all 34 cases, 23 of them had complete results of immunohistochemistry: 11 estrogen receptor (ER) positive lesions (47.8%), tenprogesterone receptor (PR) positive lesions (43.5%), seven human epidermal growth factor receptor 2 (HER-2) positive lesions (30.4%), and 20high expression(>14%) of Ki-67 (87.0%). The proportion of type luminal A was 4.3%, type luminal B was 43.5%, triple negative breast cancer (TNBC) was 30.4%, and HER-2 over expression accounted for 21.7%. Conclusions: The primary lesions of OBC usually manifested as small mass lesions, or focal, linear or segmental distribution of non-mass lesions. The positive rate of ER and PR was low, but the positive rate of HER-2 and the proliferation index of Ki-67 was high. Type luminal B is the most common molecular subtype. 目的: 探讨隐匿性乳腺癌原发癌灶的MRI表现及临床病理特征。 方法: 依据2013年MRI乳腺影像报告和数据系统对隐匿性乳腺癌患者的乳腺内病灶进行分析,研究隐匿性乳腺癌患者MRI增强后形态学特征、时间-信号强度曲线(TIC)和临床病理特征。 结果: 34例患者中,行乳腺癌改良根治术24例,其中18例在乳腺病理切片中可见原发癌灶。MRI检出原发癌灶17例,其中肿块型病变6例,直径0.6~1.2 cm(平均0.9 cm);非肿块样强化病变11例,其中线样分布4例,段样分布3例,局灶性分布3例,区域性分布1例。TIC类型Ⅰ型5例,Ⅱ型10例,Ⅲ型2例。34例隐匿性乳腺癌中,有完整免疫组化结果23例,雌激素受体(ER)阳性11例(47.8%),孕激素受体(PR)阳性10例(43.5%),人表皮生长因子受体2(HER-2)阳性7例(30.4%),Ki-67高表达(>14%)20例(87.0%)。Luminal A型1例(4.3%),Luminal B型10例(43.5%),三阴性乳腺癌7例(30.4%),HER-2过表达5例(21.7%)。 结论: 隐匿性乳腺癌灶MRI常表现为体积较小的肿块型病变及局灶性分布、线样分布或段样分布的非肿块样强化病变,ER、PR阳性率低,而HER-2阳性率高,Ki-67指数较高,其分子亚型构成以Luminal B型最为多见。.
引用
- Zhang JJ, Yang XT, Du XS, et al. [MRI findings and pathological features of occult breast cancer]. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 29365416. doi:10.3760/cma.j.issn.0253-3766.2018.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。